Introduction
============

*Klebsiella pneumoniae* is an important causative agent of hospital-acquired infections, including severe pneumonia, urinary tract infection as well as septicemia and wound infections ([@B1], [@B2]). This bacterium can survive in hospitals, persist on environmental surface and colonize different parts of human body. Therefore, transmission of this opportunistic pathogen can easily occur among patients via the hands of healthcare personnel. Furthermore, the increased use of antibiotics and persistent exposure of *K. pneumoniae* to a number of antimicrobial agents, facilitating the emergence of multidrug-resistant strains, which has further intensified the infection control strategies in many health care settings ([@B3]).

The most important resistant isolates of *K. pneumoniae* are carbapenem and cephalosporin resistant strains ([@B4]). These strains can cause serious infections in immunocompromised patients, in association with prolonged hospital, stays, limited therapeutic options and increased mortality rates, ranging from 12% to as high as 72%, depending on the study population ([@B5]--[@B9]). In these regards, a reliable estimate of the extent of drug resistant isolates of *K. pneumoniae* is needed for the programmatic management of drug resistant strains within the context of national infection control programs.

This study was designed to determine the prevalence of drug resistant strains of *K. pneumoniae* in Iran according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement ([@B10], [@B11]).

Methods
=======

Search strategies
-----------------

We conducted the search using PubMed, Web of Science, Cochrane library and Scopus for all studies addressing the prevalence of drug resistant strains of *K. pneumoniae* in Iran, from Jan 1998 to Nov 2014. The applied keywords include *Klebsiella*, *Klebsiella pneumoniae*, antibiotic resistance, antibiotic susceptibility, and Iran. Iranian databases including Iranmedex and Scientific Information Database (SID) were also searched (with Persian keywords).

Inclusion and exclusion criteria
--------------------------------

We considered all the original articles about the incidence rate of drug resistant strains of *K. pneumoniae* from hospital-acquired infections in Iran. These articles should reference to the standard method, which recommended by clinical and laboratory standards Institute (CLSI) for drug susceptibility testing of *K. pneumoniae* against; carbapenems, cephalosporins and the other most used antimicrobial agents. Due to the following reasons, some studies were excluded from our analysis. Articles have focused only on community acquired *K. pneumonia*e or focused only on *non-K. pneuomoniae* stains, and studies not used CLSI recommended drug susceptibility testing methods. Furthermore, case reports, meta-analyses or systematic reviews, letters to editor, review articles, non-English or Persian studies, and duplicate publication, were also excluded.

Data extraction and definitions
-------------------------------

The extracted data in current study include the first author's name, the publication time, year of study, number of samples, and prevalence of drug resistant strains of *K. pneumoniae*. Two authors extracted data from all of the included studies independently and a third investigator reviewed results.

Statistical analysis
--------------------

The comprehensive meta-analysis software (ver. 2.0) was used to analyse the data. Because of the heterogeneity between studies, random effects models were used and tested with the Cochrane Q test. Moreover, Egger weighted regression and Begg rank correlation tests were performed to assess possible publication bias.

Results
=======

Initially, 1353 articles were collected ([Fig. 1](#F1){ref-type="fig"}). However, in a secondary screening, 1308 of them were excluded according to duplication, title, and abstract evaluation, and full-text of 45 papers was evaluated. Finally, 27 articles describing the prevalence of the ceftazidime- and/or imipenem-resistant strains of *K. pneumoniae* were selected for meta-analysis ([Table 1](#T1){ref-type="table"}). In all included studies, antimicrobial susceptibility testing had been performed using disc diffusion method as recommended by CLSI guidelines. Most of the studies were done in Tehran (n=11) compared with Isfahan (n=4), Fars (n=3), East Azerbaijan (n=2), Semnan (n=2), Hamadan (n=2), K. Boyer Ahmad (n=1), West Azerbaijan (n=1) and Kerman (n=1). [Fig. 2](#F2){ref-type="fig"} shows the distribution of drug-resistant strains of *K. pneumoniae* in different regions of Iran. The prevalence of imipenem and ceftazidime resistance was found to be 3.2% (95% CI, 1.5--6.5) and 55.7% (95% CI, 46.9--64.1), respectively ([Table 2](#T2){ref-type="table"}). [Fig. 3](#F3){ref-type="fig"} and [4](#F4){ref-type="fig"} show the forest plot of the Meta-analysis of imipenem and ceftazidime resistant *K. pneumoniae*.

![Summary of the literature search and study selection](IJPH-47-317-g001){#F1}

![Distribution of drug-resistant *Klebsiella pneumoniae* in different regions of Iran](IJPH-47-317-g002){#F2}

![Forest plot of the meta-analysis on imipenem resistance. CI, confidence interval](IJPH-47-317-g003){#F3}

![Forest plot of the meta-analysis on ceftazidime resistance. CI, confidence interval](IJPH-47-317-g004){#F4}

###### 

Included studies after full-text evaluation

  ***References***   ***Published time***   ***Enrollment time***   ***Province***               ***Total number of samples***   ***Isolates of Klebsiella penomoniae***   ***Number of Ceftazidime* (%)**   ***Resistance to Imipenem* (%)**
  ------------------ ---------------------- ----------------------- ---------------------------- ------------------------------- ----------------------------------------- --------------------------------- ----------------------------------
  [@B12]             2007                   2002--2005              Tehran                       200                             33                                        24(73)                            \-
  [@B13]             2005                   2003--2004              Tehran                       115                             100                                       28(28)                            0(0)
  [@B14]             2011                   2006--2009              Tehran                       250                             250                                       95(38)                            3(1)
  [@B15]             2010                   2007--2008              Tehran                       101                             25                                        23(92)                            2(8)
  [@B16]             2008                   2007--2008              Tehran                       164                             40                                        20(50)                            \-
  [@B17]             2009                   2007--2008              Tehran                       65                              30                                        23(77)                            0(0%)
  [@B18]             2010                   2008--2009              Tehran                       81                              62                                        53(85)                            0(0%)
  [@B19]             2014                   2009--2010              Tehran                       50                              30                                        26(87)                            \-
  [@B20]             2013                   2009--2011              Tehran                       360                             45                                        34(76)                            3(7)
  [@B21]             2014                   2011--2012              Tehran                       83                              83                                        46(55)                            20(24)
  [@B22]             2012                   2011--2012              Tehran                       120                             45                                        21(47)                            \-
  [@B23]             2011                   2009--2010              Isfahan                      211                             30                                        7(23)                             \-
  [@B24]             2014                   2013--2014              Isfahan                      123                             15                                        \-                                0(0)
  [@B25]             2011                   2009--2010              Isfahan                      167                             36                                        23(64)                            0(0)
  [@B26]             2013                   2010--2011              Isfahan                      61                              61                                        30(49)                            \-
  [@B27]             2013                   2009--2010              Fars                         571                             60                                        28(47)                            1(2)
  [@B28]             2012                   2009--2010              Fars                         328                             144                                       \-                                12(8)
  [@B29]             2013                   2009--2010              Fars                         60                              60                                        28(47)                            1(2)
  [@B30]             2008                   2007--2008              East Azarbaijan              88                              47                                        43(91)                            0(0)
  [@B31]             2010                   2008--2009              East Azarbaijan              72                              72                                        58(81)                            \-
  [@B32]             2010                   2007--2008              Semnan                       310                             76                                        18(24)                            \-
  [@B33]             2009                   2007--2008              Semnan                       382                             107                                       21(20)                            \-
  [@B34]             2014                   2007--2008              Kerman                       413                             75                                        52(69)                            2(3)
  [@B35]             2005                   1999--2001              West Azarbaijan              251                             19                                        3(16)                             \-
  [@B36]             2013                   2010--2012              Kohgiluyeh and Boyer Ahmad   202                             180                                       93(52)                            \-
  **[@B37]**         2013                   2011--2012              Hamedan                      120                             120                                       44(37)                            0(0)
  **[@B38]**         2009                   2004--2006              Hamedan                      209                             30                                        \-                                2(7)

###### 

The prevalence of imipenem and ceftazidime resistance among *Klebsiella pneumoniae*

  ***Subgroups***                               ***No. of study***   ***Prevalence of drug resistance (95% CI)***   ***n/N\****   ***Heterogeneity Test***   ***Egger's test for publication bias***         
  --------------------------------------------- -------------------- ---------------------------------------------- ------------- -------------------------- ----------------------------------------- ----- ---------
  Overall effects of resistant to imipenem      16                   3.2 (1.5--6.5)                                 46/1182       75.9                       \<.001                                    5.1   0.00016
  Overall effects of resistant to ceftazidime   24                   55.7 (46.9--64.1)                              841/1686      92.2                       \<.001                                    2.4   0.02454

CI, confidence interval; n, number of events (drug resistance); N, total number of *Klebsiella pneumoniae* from the included studies

Some evidence for publication bias for imipenem and ceftazidime was observed (*P*\<0.05 for Begg rank correlation analysis; *P*\<0.05 for Egger weighted regression analysis) ([Fig. 5](#F5){ref-type="fig"}, [6](#F6){ref-type="fig"}). The resistance of *K. pneumoniae* to other important antimicrobial agents is shown in [Table 3](#T3){ref-type="table"}.
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###### 

Drug resistance status in *Klebsiella pneomoniae*

  ***References***   ***Enrollment time***   ***Case number***   ***Carbapenem***   ***Cephalosporins***   ***Aminogly-cosides***   ***Fluoroquinolones***   ***Monobactam***   ***Penicillins***   ***Macrolid***   ***Cotrimoxazole***                                       
  ------------------ ----------------------- ------------------- ------------------ ---------------------- ------------------------ ------------------------ ------------------ ------------------- ---------------- --------------------- -------- -------- -------- -------- --------
  **[@B12]**         2002--2005              33                  \-                 \-                     24                       19                       19                 \-                  14               21                    15       26       \-       14       \-
  **[@B13]**         2003--2004              100                 0                  \-                     28                       \-                       20                 \-                  9                30                    20       \-       \-       31       \-
  **[@B14]**         2006--2009              250                 3                  \-                     95                       91                       86                 100                 53               82                    85       \-       \-       \-       \-
  **[@B15]**         2007--2008              25                  2                  \-                     23                       22                       23                 22                  24               \-                    17       \-       24       13       18
  **[@B16]**         2007--2008              40                  \-                 \-                     20                       \-                       19                 \-                  8                14                    12       \-       40       16       20
  **[@B17]**         2007--2008              30                  0                  \-                     23                       6                        20                 25                  20               16                    18       \-       30       18       18
  **[@B18]**         2008--2009              62                  0                  \-                     53                       56                       47                 44                  14               30                    32       59       \-       16       47
  **[@B19]**         2009--2010              30                  \-                 \-                     26                       25                       \-                 \-                  16               17                    26       \-       30       \-       \-
  **[@B20]**         2009--2011              45                  3                  13                     34                       37                       \-                 33                  11               \-                    32       32       \-       \-       38
  **[@B21]**         2011--2012              83                  20                 20                     46                       50                       49                 30                  12               29                    46       49       65       \-       \-
  **[@B22]**         2011--2012              45                  \-                 \-                     21                       \-                       \-                 \-                  \-               \-                    43       \-       \-       23       31
  **[@B23]**         2009--2010              30                  \-                 \-                     7                        5                        \-                 \-                  0                7                     6        \-       21       10       8
  **[@B24]**         2013--2014              15                  0                  0                      \-                       15                       \-                 15                  8                \-                    12       \-       15       10       \-
  **[@B25]**         2009--2010              36                  0                  \-                     23                       21                       \-                 22                  12               \-                    13       \-       33       7        28
  **[@B26]**         2010--2011              61                  \-                 \-                     30                       49                       37                 \-                  \-               \-                    \-       \-       \-       \-       \-
  **[@B27]**         2009--2010              60                  1                  \-                     28                       34                       \-                 29                  5                8                     13       19       60       \-       26
  **[@B28]**         2009--2010              144                 12                 \-                     \-                       \-                       \-                 \-                  61               65                    42       \-       23       \-       43
  **[@B29]**         2009--2010              60                  1                  \-                     28                       34                       \-                 29                  5                8                     13       19       60       \-       26
  **[@B30]**         2007--2008              47                  0                  \-                     43                       42                       44                 39                  5                \-                    \-       41       \-       \-       \-
  **[@B31]**         2008--2009              72                  \-                 \-                     58                       \-                       \-                 \-                  31               53                    31       \-       \-       68       69
  **[@B32]**         2007--2008              76                  \-                 \-                     18                       19                       \-                 \-                  \-               19                    35       \-       73       \-       41
  **[@B33]**         2007--2008              107                 \-                 \-                     21                       24                       \-                 \-                  \-               19                    21       \-       97       \-       27
  **[@B34]**         2007--2008              75                  2                  \-                     52                       25                       \-                 27                  \-               48                    21       \-       \-       \-       35
  **[@B35]**         1999--2001              19                  \-                 \-                     3                        \-                       \-                 \-                  0                5                     3        \-       14       \-       3
  **[@B36]**         2010--2012              180                 \-                 41                     93                       87                       81                 \-                  40               65                    31       83       \-       138      108
  **[@B37]**         2011--2012              120                 0                  \-                     44                       50                       52                 30                  \-               32                    20       52       \-       \-       49
  **[@B38]**         2004--2006              30                  2                  \-                     \-                       \-                       3                  3                   11               13                    7        19       60       \-       \-
  **Mean**           \-                      \-                  46                 74                     841                      711                      500                448                 359              581                   613      399      645      364      635
  **Rate**                                                       (3.2)              (18.9)                 (55.7)                   (49.9)                   (47.1)             (47.8)              (25.8)           (36.3)                (34.8)   (55.4)   (82.2)   (54.5)   (51.8)

**Abbreviations**: 1. IMP, imipenem; 2. MEM, meropenem; 3.CAZ, ceftazidime; 4. CTX, cefotaxime; 5. CRO, ceftrixone; 6. CPM, cefepime; 7. AMK, amikacin; 8. GM, gentamycin; 9.CIP, ciprofloxacin; 10. AZT, aztreonam; 11. AMP, ampicillin; 12. NF, nitrofurantoin; 13.SXT/TMP, trimethoprim/sulfamethoxazole

Discussion
==========

The emergence and spread of carbapenem and cephalosporin resistant strains of *K. pneumoniae* are a considerable threat to public health ([@B2]). The major goal of this systematic review was to evaluate the current situation and distribution of drug-resistant *K. pneumoniae* in Iran.

This analysis showed that 3.2% *K. pneumoniae* isolates from Iran was resistant to imipenem and 55.7% to ceftazidime. Thereby despite ceftazidime, the imipenem remains as a powerful weapon against *K. pneumoniae* isolates in Iran. In the current study more than half of *K. pneumoniae* isolates were resistant to other important antimicrobial agents such as aztreonam (55.4 %), nitrofurantoin (54.5%) and cotrimoxazole (51.8%), we highly recommend that antimicrobial test should be performed prior to any antibiotic prescription in *K. pneumonia* infections. Very low number of *K. pneumonia* population (17.8%) were sensitive to ampicillin suggesting ampicillin is not effective drug for empiric treatment of *K. pneumonia infections* unless we use it in combination with other relevant drugs.

The relatively high rates of drug resistant isolates of *K. pneumoniae* observed in this study may have several negative effects on public health issues ([@B39]). For example, this could cause difficulty in treating *K. pneumoniae* associated infections since fewer effective drugs are available for treating those highly drug-resistant strains. Unfortunately, these microorganisms are even showing rising rates of resistance to new expensive antibiotics subsequently considered the treatment of choice ([@B40]). This is due to the widespread use of broad-spectrum antibiotics in health care settings for empiric treatment of infections. Furthermore, patients infected with these pathogens require prolonged antimicrobial therapy that has considerable implications for the individual patient and for the health care settings. Finally, infections due to these highly resistant strains are reported to be associated with higher morbidity and mortality rates ([@B41]). In Iran, 50000 people die each year because of multidrug-resistant bacterial infections and that this costs Iranian economy 2.5 million dollars annually ([@B4]).

Some important reasons for the increasing rates of drug resistant isolates in Iran include limited infection surveillance programs, the lack of communication between physicians and microbiologists, lack of standardized or accepted criteria to determine drug resistant isolates, limited laboratory facilities, and poor sanitation. Therefore, active infection control committee, appropriate antimicrobial therapy, and improvement of hygiene condition will prevent or lower the emergence of antimicrobial-resistant pathogens ([@B42]).

Current review was carried out according to provinces of Iran and the published time. Because of many hospitals and health care centers in Tehran Province, Iran, patients from other provinces come to Tehran for better treatment. Therefore, most of the studies in this analysis belonged to Tehran, where the ceftazidime- and/or imipenem-resistant strains of *K. pneumoniae* mostly reported by researchers.

Conclusion
==========

There is a relatively high prevalence of drug resistant *K. pneumoniae* isolates in Iran. Thus, a high degree of awareness among physicians and microbiologists, active infection control committee, appropriate antimicrobial therapy, improvement of hygiene condition and monitoring of drug resistant isolates are urgently needed in order to better control the emergence and spread of drug-resistant *K. pneumoniae* isolates in hospital settings.
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